Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Saad Z. Usmani"'
Autor:
Indrajeet Singh, Alicia J. Allred, Sen Zhuang, Jordan M. Schecter, Enrique Zudaire, Jesus G. Berdeja, Syed Rizvi, Arnob Banerjee, Jenna D. Goldberg, Tzu-Min Yeh, Andrzej Jakubowiak, Deepu Madduri, Jeffrey R. Infante, Xiaohu (Frank) Fan, Saad Z. Usmani, Sundar Jagannath
Publikováno v:
Blood. 134:577-577
JNJ-68284528 (JNJ-4528) is a chimeric antigen receptor T cell (CAR-T) therapy containing two BCMA-targeting single-domain antibodies designed to confer avidity. A first-in-human phase 1 study (LEGEND-2) conducted in China of LCAR-B38M, an identical C
Autor:
Issam Hamadeh, Shebli Atrash, Jill Eddy, James T. Symanowski, Saad Z. Usmani, Daniel Slaughter, Reed Freind, Peter M. Voorhees, Justin Arnall, Lauren Minard, NDaiye Ami, Myra M. Robinson, Rajesh Banderudrappagari, Chelsea Sprouse, Maham Ashraf Khan, Edward A. Copelan, Belinda R. Avalos, Manisha Bhutani, Jordan Robinson
Publikováno v:
Blood. 132:5582-5582
BACKGROUND: Multiple Myeloma (MM) is a heterogenous disease with variable outcomes based on both disease biology and burden. The revised international staging system (R-ISS) can distinguish 5-year overall survival (OS) however, it does not incorporat
Publikováno v:
Web of Science
Background: To fully evaluate the potential benefit of novel agents for the treatment of patients with multiple myeloma (MM) who are heavily pretreated and refractory, it is important to understand the outcomes of this patient population based on cur
Autor:
Joshua Epstein, Antje Hoering, Rachael Sexton, John Crowley, Shmuel Yaccoby, Saad Z. Usmani, Bart Barlogie, Frits van Rhee, Donald J. Johann, Pingping Qu
Publikováno v:
Blood. 120:3953-3953
Abstract 3953 PC-GEP provides great insight into MM heterogeneity as defined by 7 distinct molecular subgroups, along with clinical correlates and prognosis, as identified by the GEP-70 model. As is now increasingly appreciated in MM, a close interac
Autor:
Christoph Heuck, Rachael Sexton, Frits van Rhee, Pingping Qu, Sarah Waheed, Joshua Epstein, Bart Barlogie, John D. Shaughnessy, Qing Zhang, John Crowley, Saad Z. Usmani, Madhav V. Dhodapkar
Publikováno v:
Blood. 120:2933-2933
Abstract 2933 Monoclonal gammopathy of undetermined significance (MGUS), a premalignant plasma cell dyscrasia, is differentiated from asymptomatic multiple myeloma (AMM), based on the level of monoclonal immunoglobulin (M spike) and bone marrow plasm
Autor:
Alan Mitchell, Jameel Muzaffar, Nisar Ahmad, Sajjad Haider, Bart Barlogie, Senu Apewokin, Alejandro Restrepo, John Crowley, Monica Grazziutti, Al-Ola Abdallah, Frits van Rhee, Aziz Bakhous, Surachit Kumar, Zainab Shahid, Saad Z. Usmani, Sarah Waheed, Shebli Atrash
Publikováno v:
Blood. 120:1850-1850
Abstract 1850 The use of the word cure when discussing MM therapy remains taboo. Albeit most investigators applaud the enormous improvement in clinical outcomes ushered in initially by autotransplant-supported high-dose melphalan. Additionally, the i
Autor:
Christoph Heuck, John Crowley, Yazan Alsayed, Qing Zhang, Frits van Rhee, Antje Hoering, Bart Barlogie, Bijay Nair, Sarah Waheed, Jackie Szymonifka, John D. Shaughnessy, Saad Z. Usmani, Elias Anaissie
Publikováno v:
Blood. 118:988-988
Abstract 988 Background: Dexamethasone remains a key component of myeloma therapy. We previously showed that expression levels of the nuclear glucocorticoid receptor NR3C1 were associated with OS and PFS in patients treated on Total Therapy 3 (TT3).
Autor:
Elias Anaissie, Yazan Alsayed, Jackie Szymonifka, Bart Barlogie, Sarah Waheed, Bijay Nair, Monica Grazziutti, Saad Z. Usmani, Frits van Rhee, Antje Hoering
Publikováno v:
Blood. 116:1969-1969
Abstract 1969 Background: High-risk MM remains a very difficult clinical challenge despite advances in therapy for the majority of patients who have benefited from the use of high-dose therapies and novel agents. Recognizing that MM from the outset r